News & Updates
Filter by Specialty:
Sacituzumab govitecan confers OS benefit for HR+/HER2– metastatic breast cancer
In the second interim overall survival (OS) analysis of the phase III TROPiCS-02 study, sacituzumab govitecan (SG) – a first-in-class Trop-2*-directed antibody-drug conjugate approved for triple-negative metastatic breast cancer (mBC) with ≥2 prior therapies (≥1 in the metastatic setting) – conferred an OS benefit for pretreated HR+/HER2– mBC, compared with treatment of physician’s choice (TPC**).
Sacituzumab govitecan confers OS benefit for HR+/HER2– metastatic breast cancer
12 Oct 2022Osimertinib plus selumetinib shows promise in advanced NSCLC
The combination of osimertinib plus selumetinib exhibits antitumour activity in patients with MET-negative, EGFRm advanced nonsmall cell lung cancer (NSCLC), with the safety profile consistent with the reported safety data for the drugs, according to data from the small open-label, phase Ib study.
Osimertinib plus selumetinib shows promise in advanced NSCLC
11 Oct 2022ERAS protocol safe, shortens postoperative stay in elderly gastric cancer patients
Among older adults undergoing gastrectomy for gastric cancer, employing the Enhanced Recovery After Surgery (ERAS) protocol leads to a shorter postoperative hospital stay without introducing new safety signals, a recent study has found.
ERAS protocol safe, shortens postoperative stay in elderly gastric cancer patients
08 Oct 2022Sugemalimab for stage III NSCLC: Efficacy, safety signals sustained in final PFS analysis
In the final progression-free survival (PFS) analysis of the GEMSTONE-301 study, sugemalimab demonstrated sustained efficacy and safety as consolidation treatment for individuals with unresectable stage III non-small cell lung cancer (NSCLC) whose disease had not progressed following either concurrent chemoradiotherapy (cCRT) or sequential CRT (sCRT).
Sugemalimab for stage III NSCLC: Efficacy, safety signals sustained in final PFS analysis
07 Oct 2022Inflammation ups risk of chemo-induced decline in frailty status in older women with breast cancer
Robust older women with early breast cancer who have high prechemotherapy levels of both interleukin-6 (IL-6) and C-reactive protein (CRP) are >3 times more likely to experience chemotherapy-induced decline in frailty status than their counterparts with low levels of these inflammatory markers, a prospective study has shown.